UnitedHealth Group Incorporated (UNH) stock reported first-quarter 2026 adjusted EPS of $7.23, beating the $6.58 consensus estimate by roughly 10%, on revenue of $111.7B versus the $109.6B expected. Management raised full-year 2026 adjusted EPS guidance to above $18.25, topping the $17.86 Street estimate. Shares surged over 8% on the session, and are continuing to hold gains above $350 as of this morning.
Key Drivers of the UNH Stock Move
- Main Catalyst: Q1 2026 earnings decisively beat on both EPS and revenue, with easing medical costs cited as a key driver. FY26 guidance was raised above analyst consensus, reinforcing management’s confidence in the cost structure.
- Bull Case: Medical cost trends are improving, the 2.48% CMS Medicare Advantage rate hike for 2027 provides a tailwind for the back half, and the company is accelerating rural hospital payment timelines, potentially expanding its provider network appeal.
- Bear Case: Despite the beat, year-over-year EPS growth was nearly flat (+0.42%), revenue growth was modest (+1.96% YoY), and Baird maintained its Underperform with a $287 price target, calling the stock fairly valued or stretched after the pop.
The post-earnings setup shows a stock that was deeply oversold heading into the print, having traded near $300 in early April. The recovery is sharp, but the stock remains well below its 2025 highs. Risks persist around Medicaid policy uncertainty (the Trump administration’s CMS funding restrictions for noncitizens take effect October 2026), headline risk tied to the ongoing scrutiny of health insurer practices, and the possibility that medical cost ratios re-accelerate into year-end. The Q4 2025 GAAP EPS of $2.11 (a 69% YoY drop) is a reminder that one-time charges can hit hard in this sector.
UNH Smart Money Activity
Insider activity since January has been almost entirely comprised of stock awards to directors and executives, with no open-market cash purchases or sales of note. The most notable insider award was CFO Wayne DeVeydt receiving $2.5M in stock on Feb 23. On the government side, the most active trader has been Rep. Ro Khanna (D), who has been actively swinging the name with a series of alternating purchases and sales ranging from $1K to $50K since January. Republican Sen. Markwayne Mullin made a meaningful purchase of $50K to $100K on Feb 25. Overall, congressional activity is mixed with no clear directional signal.
UNH Unusual Options
On earnings day (April 21), options flow was exceptionally heavy and notably mixed. The two largest single prints were a bullish $644.9K sweep into UNH Jan ’27 $300 Calls and a bearish $662K sweep into Dec ’26 $300 Puts, suggesting institutions are hedging in both directions around the elevated post-earnings price. A $820.3K bullish trade hit the Sep ’26 $260 Calls, deeply in-the-money, which reads as a large position roll or replacement. Today (Apr 22), the single largest print so far is a $1.4M bearish trade on Jul ’26 $370 Calls at the bid, alongside continued bullish sweeps into Jan ’27 $410 and $460 Calls. The mix of short-dated bearish prints and longer-dated bullish positioning suggests the market is pricing in near-term consolidation while betting on a continued recovery over the next 6 to 12 months.
UNH Analyst Focus
Post-earnings, six firms raised price targets on April 22 alone. Raymond James upgraded to Outperform on April 1 ahead of earnings. The lone dissenter remains Baird at Underperform. The median price target across visible ratings clusters around $373 to $400, implying roughly 5% to 15% upside from current levels near $353. No downgrades have been issued in 2026.
UNH Seasonality
Based on monthly data going back to January 2014 (12 to 13 samples per month). April has historically been a positive month (54% win rate, +2.4% avg), and UNH is already delivering on that. The May through August stretch is historically the strongest and most consistent window for the stock. September is the weakest month of the year (33% win rate, 0.0% avg), worth monitoring as a potential headwind into fall.
UNH Relative Performance
UNH spent the majority of Q1 2026 in the bottom third of its healthcare sector peers, stuck between the 30th and 40th percentile on a trailing 12-month basis. The stock trailed most of its sector significantly while elevated medical cost fears and policy headline risk weighed on sentiment. On April 21, earnings day, the relative performance score jumped sharply to the 50th percentile, meaning UNH is now roughly in line with its healthcare sector peers on a yearly basis. A sustained move above 55 to 60 would confirm that the narrative reset is taking hold versus its peer group.
Market Update Into September 7th: Inflation Data Incoming